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Summary
Background The relationship between early-life antibiotic use and the development of wheeze and asthma has been 
reported in several studies but might arise as a consequence of bias rather than causal relationship. We investigated 
the association between antibiotic prescription and subsequent development of atopy, wheeze, and asthma 
exacerbations, and the relation of early life antibiotic prescription with anti-infective immunity and genetic variants 
on asthma susceptibility locus 17q21.
Methods Children in a population-based birth cohort were followed from birth to age 11 years. Information on 
antibiotic prescription, wheeze, and asthma exacerbations was extracted from medical records, and the eﬀ ect of 
antibiotic prescription assessed with longitudinal analyses. We assessed immune responses of peripheral blood 
mononuclear cells, taken at age 11 years, to viruses (rhinovirus and respiratory syncytial virus; RSV) and bacteria 
(Haemophilus inﬂ uenzae and Streptococcus pneumoniae) in children who either received at least one or no antibiotic 
prescriptions in infancy. Finally, we assessed the association of 17q21 polymorphisms with antibiotic prescription.
Findings Of 984 families who gave consent, we extracted data for 916 children. We noted signiﬁ cantly higher risk of 
physician-conﬁ rmed wheezing after antibiotic prescription (hazard ratio [HR] 1·71, 95% CI 1·32–2·23; p<0·0001) 
and severe wheeze or asthma exacerbation after antibiotic prescription (HR 2·26, 95% CI 1·03–4·94; p=0·041). In 
children who wheezed, the hazards of exacerbations (2·09, 1·51–2·90; p<0·0001) and admissions to hospital (2·64, 
1·49–4·70; p=0·0009) were signiﬁ cantly increased in the 2 years after the ﬁ rst antibiotic prescription. Children who 
received antibiotics in infancy had signiﬁ cantly lower induction of cytokines, which are important in host defence 
against virus infections to both RSV and rhinovirus; there were no diﬀ erences in antibacterial responses. Variants in 
17q21 were associated with an increased risk of early life antibiotic prescription.
Interpretation The association between antibiotics and asthma might arise through a complex confounding by 
indication. Hidden factors that may increase the likelihood of both early life antibiotic prescription and later asthma 
are an increased susceptibility to viral infections consequent upon impaired antiviral immunity and genetic variants 
on 17q21.
Funding Moulton Charitable Foundation and Medical Research Council.
Introduction
The increase in the risk of asthma in children who 
received antibiotics in infancy has been reported in 
several studies. This topic has been a subject of at least 
three systematic reviews, which reported conﬂ icting 
results between diﬀ erent reports, and called for further 
longitudinal studies to provide deﬁ nitive answers.1–3 
Several factors might account for contradictory ﬁ ndings, 
including study design, the deﬁ nition of asthma, and the 
age at which asthma was assessed.3 Retrospective and 
cross-sectional studies showed stronger association than 
prospective studies,1,2 raising the possibility that bias 
rather than causal mechanisms could explain the 
reported associations. Two types of bias are of particular 
interest: reverse causation, in which early asthma 
symptoms cause antibiotic prescription, and confounding 
by indication, in which another hidden factor is both an 
indication for antibiotic prescription and a risk for 
subsequent asthma.3,4 One systematic review concluded 
that both reverse causation and confounding by 
indication led to overestimation of the association 
between antibiotics and asthma, and restricting the 
meta-analysis to studies in which these biases were 
unlikely rendered the ﬁ ndings non-signiﬁ cant.3
Infections with respiratory viruses might in part 
explain the association between antibiotics and asthma 
through confounding by indication.5 The most common 
indication for antibiotic prescription in children is 
respiratory tract infection,6 and about 80% of children 
presenting to a physician with cough and fever have an 
identiﬁ able viral cause.7 Virus infections are also 
intimately linked with asthma development and 
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exacerbations,8,9 and it has been proposed that some 
respiratory virus infections could cause asthma.10 We 
have previously shown that antiviral immunity is 
impaired in asthma,11,12 and these impairments are related 
to the severity of asthma exacerbation.11 Genetic variants 
in the chromosomal 17q21 locus, which have been 
identiﬁ ed as the most consistent genetic risk factor for 
asthma,13 are also associated with susceptibility to early 
life respiratory illnesses.14 It has recently been reported 
that the association of these variants with childhood-
onset asthma might be conﬁ ned to children with 
rhinovirus wheezing illness.15
We sought to further clarify the complex relation 
between early life antibiotic use and asthma. We postulated 
that antibiotic prescription in early life is a proxy marker 
of impaired antiviral immunity and increased 
susceptibility to recurrent or more severe viral infections, 
which might, in part, be genetically determined, and that 
this susceptibility to viral infection (rather than antibiotic 
prescription or a virus per se) increases the risk for 
persistence of asthma symptoms and severe asthma 
exacerbations. To address our hypotheses, we explored the 
association between antibiotic prescription and the 
development of wheezing, severe asthma exacerbations, 
and atopy during childhood; investigated whether there 
are diﬀ erences in antiviral and antibacterial immune 
responses between children who received antibiotics in 
infancy compared with those who did not; and explored 
the association between antibiotic prescription and 
polymorphisms in chromosomal locus 17q21.
Methods
Participants 
Manchester Asthma and Allergy Study (MAAS) is a 
population-based birth cohort16 (registry number 
ISRCTN72673620). Children were recruited prenatally, 
and were born between April 20, 1995, and April 13, 2000. 
The study was approved by Local Ethics Committee and 
parents gave written informed consent.
Procedures 
Participants attended clinical follow-ups at ages 1, 3, 5, 8, 
and 11 years. Validated questionnaires were interviewer-
administered to collect information on parentally reported 
symptoms, physician-diagnosed illnesses, and treatments 
received. We ascertained sensitisation to allergens by skin 
prick testing at ages 3, 5, 8, and 11 years (house dust mite 
[Dermatophagoides pteronyssinus], cat, dog, grasses, 
moulds, milk, and egg [Bayer, Elkahrt, IN, USA]).
We extracted data from electronic and paper-based 
primary care medical records, including antibiotic 
prescriptions (type, dose, and indication), episodes of 
wheeze, oral corticosteroid prescriptions, emergency 
department admissions, and asthma or wheeze-related 
admissions to hospital. Age in days at the time of each 
event was recorded. Further information on data 
extraction is available in the appendix. Panel 1 lists the 
deﬁ nition of variables.
Peripheral blood mononuclear cells (PBMCs) were 
collected at age 11 years and cryopreserved. Rhinovirus 
serotypes 1B (minor group) and 16 (major group) and 
respiratory syncytial virus (RSV) A2 strain were grown in 
HeLa and Hep2 cells.19 Cells were thawed and distributed 
in 96-well plates (2 × 10⁵ cells per well). Media control, 
rhinovirus 1B, rhinovirus 16, RSV (all at a multiplicity of 
infection [ratio of infectious agents to infection targets] 
of 1), Haemophilus inﬂ uenzae (ATTC strain 49247), and 
Streptococcus pneumoniae (strain D39; both at 10⁶ colony-
forming units (CFU) per mL) were used as stimuli. 
Supernatants were harvested 24 h after stimulation and 
interferon α, interferon γ, interferon-γ-induced protein 10 
(IP10), interleukin 1β, interleukin 6, and tumour necrosis 
factor (TNF) α (antiviral response), and interleukin 1β, 
interleukin 6, interleukin 8, interferon γ, and TNFα 
(bacterial response) levels were measured with the Meso 
Scale Discovery Multi-array (Rockville, MD, USA). 
Further information is available in the appendix.
Based on ﬁ ndings from previous studies,13, 15 we selected 
four single nucleotide polymorphisms (SNPs; rs11557467, 
rs7216389, rs4795405, rs3859192). We genotyped the 
whole cohort with Single Base Extension method 
(Sequenom, San Diego, CA, USA). Further information 
is available in the appendix.
Panel 1: Deﬁ nition of variables
Antibiotic prescription
Age (in days) when the child was prescribed the ﬁ rst antibiotic 
(medical records)
Physician-conﬁ rmed wheeze
Wheezing conﬁ rmed by the child’s general practitioner; age 
(in days) of the ﬁ rst episode was recorded (medical records)
Parentally reported wheeze
Age (in months) when the child experienced the ﬁ rst episode 
of wheezing (questionnaires)
Severe wheeze or asthma exacerbation
Receipt of oral corticosteroids for at least 3 days, admission 
to hospital, or emergency department visit because of 
asthma or wheeze needing treatment with oral steroids17 
(medical records)
Wheeze phenotypes
We used prospectively collected data to assign children into 
diﬀ erent wheeze phenotypes: no wheezing (no wheeze at 
any time), transient early wheezing (wheezing during the 
ﬁ rst 3 years, with no wheezing after age 3 years), late-onset 
wheezing (no wheeze during the ﬁ rst 3 years, reported 
wheezing at age 5 years or later), and persistent wheezing 
(wheezing throughout childhood)18
Atopy
Wheal at least 3 mm greater than negative control to at least 
one allergen during skin prick testing
See Online for appendix
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916 GP records collected
102 excluded from analysis (randomly assigned to primary prevention study)
   14 excluded
 8 premature births (<36 gestational weeks)
 4 signiﬁcant heart disease
 1 signiﬁcant neonatal respiratory illness
 1 primary immune deﬁciency
800 children for analysis
106 did not participate in the 11 year follow-up
   55 responded via postal questionnaires
 639 children attended clinic or had home visit 
 at age 11 year follow-up
264 children refused to give blood samples
375 blood samples available
24 non-viable samples excluded
231 children with PBMCs included in analysis
66 samples with insuﬃcient volume for PBMC experiment
54 samples analyzed in a separate experimental batch
255 children with PBMCs
Single child practices: postal collection—63 children
13 failed to reply
 2 declined
 3 moved no PCT ethics
 3 moved to new GP
42 records received by post
GP practices with >1 child: to visit 921 children 
 in 131 GP practices
 2 children: 1 GP practice refused access
 7 children: 3 GP practices failed to reply
 5 moved (no PCT ethics)
 23 moved to GP practice already visited
 1 could not be traced
 9 partial records  as no access to paper records
866 collected at GP premises
      8 received by post (practice refused access to premises)
1499 couples met inclusion criteria (<10 weeks 
            of pregnancy maternal age >18 years)
288 declined
   27 lost to follow up between recruitment and birth
1184 children with some evaluable data
1087 children followed prospectively from birth
All parents and children approached to consent
for GP records information collection
66 children moved (no PCT ethics)
984 children for GP records extraction
37 children no consent
PCT ethics approval to access GP records
Figure 1: Study proﬁ le
PCT=primary care trust. GP=general practitioner. PBMC=peripheral blood mononuclear cell.
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Statistical analysis
Cox models (Stata 12.2) were used to assess the hazard 
ratios (HRs) of events (physician-conﬁ rmed wheeze, 
parentally reported wheeze, severe wheeze, or asthma 
exacerbation) occurring before and after the ﬁ rst antibiotic 
prescription. To control for reverse causation, we excluded 
children in whom the event occurred within 14 days after 
receiving their ﬁ rst antibiotic (15 excluded for wheeze, two 
for exacerbations, two for hospital admissions). We 
estimated HRs and 95% CIs (independently for each 
outcome) for time-varying binary variables representing 
“time before” and “time after” the ﬁ rst antibiotic 
prescription, allowing us to assess whether the probability 
of an event was greater before or after receiving antibiotics; 
ﬁ rst antibiotic prescription in each of four age groups 
(0 to <3 months, 3 to <6 months, 6 to 12 months, and 
>12 months). This allowed us to assess whether the eﬀ ect 
of antibiotic use was modiﬁ ed by age when antibiotics 
were received; the eﬀ ect of antibiotic prescription in the 
ﬁ rst 2 years after the initial receipt, or thereafter.
The hazards of developing atopy after the ﬁ rst antibiotic 
prescription were assessed in children who had skin 
 Whole population
(n=800)
No antibiotics in 
the ﬁ rst year
(n=236)
Received antibiotic 
in the ﬁ rst year
(n=564)
p value
Number of boys 441 (55·1%) 99 (41·9%) 342 (60·6%) <0·0001
Number who were white 738/778 (94·9%) 216/230 (93·9%) 522/548 (95·3%) 0·44
Duration of follow up from medical records, years 9·97 (9·4–10·5) 9·91 (9·4–10·6) 10·01 (9·4–10·5) 0·92
Age at ﬁ rst antibiotic receipt, months 7·2 (4·2–12·9) 20·6 (15·1–31·1) 5·7 (3·3–8·0) <0·0001
Number of health-care encounters during the ﬁ rst year 12 (8–17) 8 (5–11) 13·5 (10–18) <0·0001
 0–10 343 (42·9%) 172 (72·9%) 171 (30·3%)
 11–20 355 (44·4%) 63 (26·7%) 292 (51·8%)
 >20 102 (12·8%) 1 (0·4%) 101 (17·9%)
Unscheduled GP encounters in the ﬁ rst year 7 (3–10) 3 (1–5) 8 (5–12) <0·0001
Scheduled GP encounters in the ﬁ rst year 4 (0–22) 4 (3–5) 5 (3–5) 0·15
Hospital admissions in the ﬁ rst year 31 (3·9%) 1 (0·4%) 30 (5·3%) <0·0001
Paternal income per year 0·06
<£10 000 113 (15·6%) 24 (10·9%) 89 (17·7%)
£10 001–20 000 270 (37·3%) 90 (40·7%) 180 (35·9%)
£20 001–30 000 203 (28·1%) 63 (28·5%) 140 (27·9%)
>£30 000 137 (18·9%) 44 (19·9%) 93 (18·5%)
Pet ownership at birth 0·81
No pets 500/783 (63·9%) 150/233 (64·4%) 349/550 (63·5%)
Cat 175/783 (22·3%) 47/233 (20·2%) 96/550 (17·5%)
Dog 141/783 (18·0%) 27/233 (11·6%) 81/550 (14·7%)
Cat and dog 33/783 (4·2%) 9/233 (3·9%) 24/550 (4·4%)
Breastfeeding 0·12
Not breastfed 233/762 (30·6%) 58/225 (25·8%) 175/537 (32·6%)
≤16 weeks 230/762 (30·2%) 68/225 (30·2%) 162/537 (30·2%)
>16 weeks 299/762 (39·2%) 99/225 (44·0%) 200/537 (37·2%)
Number who were ﬁ rstborn 359/736 (48·8%) 124/228 (54·4%) 235/508 (46·3%) 0·008
Daycare attendance 0·035
Home or childminder 227/738 (30·8%) 60/219 (27·4%) 167/519 (32·2%)
Entry to daycare <6 months 35/738 (4·7%) 8/219 (3·7%) 27/519 (5·2%)
Entry to daycare 6–12 months 82/738 (11·1%) 17/219 (7·8%) 65/519 (12·5%)
Entry to daycare >12 months 394/738 (53·4%) 134/219 (61·2%) 260/519 (50·1%)
Maternal smoking during pregnancy 114/796 (14·3%) 28/236 (11·9%) 86/560(15·4%) 0·57
Family history of allergic disease
Maternal atopy 415/774 (53·6%) 115/236 (48·7%) 300/538 (55·8%) 0·071
Maternal current asthma 94/795 (11·8%) 24/212 (10·2%) 70/559 (12·5%) 0·35
Paternal atopy 438/769 (57·0%) 143/235 (60·9%) 295/534 (55·2%) 0·15
Older sibling with asthma 85/795 (10·7%) 16/235 (6·8%) 69/560 (12·3%) 0·022
Data are n (%), mean (SD), or median (IQR). 
Table 1: Participant characteristics
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prick testing data at all four timepoints with longitudinal 
models in which antibiotic prescription was deﬁ ned as 
receipt in the ﬁ rst year, ever, or within each of the four 
age groups.
We adjusted our analyses for signiﬁ cant confounding 
factors (sex, attendance at day care, older siblings, and 
breastfeeding).
We repeated the analysis excluding children who were 
prescribed their ﬁ rst antibiotic for lower respiratory tract 
infections. Further analyses on the eﬀ ect of antibiotic 
prescription on wheeze or asthma exacerbations and 
admissions to hospital were done in children with 
parentally reported or physician-conﬁ rmed wheeze.
We investigated immune responses to viruses and 
bacteria in children who received one or more antibiotics 
or had no antibiotics in the ﬁ rst year of life. We used 
quantile regression analysis to compare median cytokine 
titres after stimulation, and Cox models to ascertain 
whether the time to ﬁ rst wheeze episode, severe asthma 
exacerbation, and hospital admission diﬀ ered between 
these two groups.
We used independent additive models in logistic 
regression analyses for each of the SNPs using the wild-
type homozygous group as the reference to assess the 
association between antibiotic prescription and variants 
in 17q21.
Role of the funding source 
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 984 families who gave consent, we extracted data for 
916 children (93%; further details in the appendix). 
Figure 1 shows the participant ﬂ ow; 102 children who 
were prenatally randomly assigned to a prevention study 
and 14 with prematurity or serious early life diseases 
were excluded. Demographic characteristics of the study 
population are presented in table 1. Of 800 participants, 
409 (51%) had at least one physician-conﬁ rmed wheeze 
episode (mean age at onset 21·9 months, range 
0·5–129·0), 448 (56%) had parentally reported wheeze 
(mean age at onset 18·9 months, 0·7–80·0), and 
529 (66%) had either. Of 469 children with complete skin 
prick testing data, 260 (55%) were always non-atopic, 
52 (11%) were atopic at a single assessment, 43 (9%) at 
two, 47 (10%) at three, and 67 (14%) at all four assessments.
780 children (98%) received at least one antibiotic 
course (120 [15%] within the ﬁ rst 3 months of life, 
303 [38%] within 6 months, 476 [60%] within 9 months, 
and 564 [71%] within the ﬁ rst year). The ﬁ rst antibiotic 
was prescribed for upper respiratory tract infections in 
434 children (54%), lower respiratory tract infections in 
214 (27%), skin infections in 64 (8%), and other 
indications in 68 (9%). Children prescribed antibiotics 
during the  ﬁ rst year of life were signiﬁ cantly less likely 
to have been breastfed for longer than 16 weeks (p=0·04) 
and signiﬁ cantly more likely to be boys, have more than 
ten health-care encounters by age 1 year, have older 
siblings, attend day care, have a sibling with asthma, and 
tended (not signiﬁ cant) to have atopic mothers and come 
from lower income families (table 1).
We noted signiﬁ cantly higher risk of physician-
conﬁ rmed and parentally reported wheezing after 
children received antibiotics (table 2). In the analyses 
by age group, the estimated HRs were consistently 
higher if antibiotic was prescribed in the ﬁ rst year of 
life. Similar results were obtained for severe wheeze or 
asthma exacerbation. For all outcomes HRs were 
signiﬁ cantly higher within the ﬁ rst 2 years after 
antibiotic prescription, but not beyond 2 years. The 
ﬁ ndings did not materially change when we excluded 
children who received their ﬁ rst antibiotic for lower 
respiratory tract infections (appendix). Similar results 
were obtained with unadjusted analysis (not shown).
Antibiotic 
prescription
Piecewise analysis of the age at antibiotic 
prescription
Time to event after the ﬁ rst antibiotic 
prescription
≤2 years >2 years
Physician-conﬁ rmed wheeze 1·71 (1·32–2·23), 
p<0·0001
1·70 (1·22–2·37), p=0·002 (<3 months);
1·54 (1·10–2·15), p=0·011 (3–<6 months);
1·68 (1·17–2·38), p=0·005 (6–12 months);
1·59 (0·97–2·61), p=0·06 (>12 months)
2·20 (1·79–2·70), 
p<0·0001
1·06 (0·81–1·37), 
p=0·69
Parentally reported wheeze 1·71 (1·33–2·21), 
p<0·0001
1·79 (1·32–2·44), p=0·0001 (<3 months);
1·69 (1·22–2·35), p=0·002 (3–<6 months);
1·64 (1·15–2·36), p=0·007 (6–12 months);
1·86 (1·16–2·98), p=0·010 (>12 months)
2·20 (1·81–2·68), 
p<0·0001
1·07 (0·83–1·38), 
p=0·59
Severe wheeze or asthma exacerbation 2·26 (1·03–4·94), 
p=0·041
2·48 (1·00–6·13), p=0·050 (<3 months);
2·57 (1·06–6·24), p=0·038 (3–<6 months);
1·85 (0·74–4·59), p=0·19 (6–12 months);
1·93 (0·69–5·38), p=0·21 (>12 months)
2·21(1·52–3·22), 
p<0·0001
1·30 (0·60–2.80), 
p=0·51
Data are hazard ratio (95% CI). Reference was no antibiotics received before given time. Analysis adjusted for sex, presence of older siblings, day care attendance, and breastfeeding.
Table 2: Antibiotic prescription and the risk of wheezing and severe asthma exacerbations
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Of 529 children who had at least one physician-
conﬁ rmed or parentally reported wheezing episode, 
severe wheeze or asthma exacer bations and hospital 
admissions were signiﬁ cantly increased in the initial 
2 years after the ﬁ rst antibiotic prescription (table 3). 
Additional analyses showed atopy at age 3 years as a 
signiﬁ cant risk factor for exacerbations (HR 4·01, 
2·43–6·59; p<0·0001) and hospital admissions (5·41, 
2·06–14·23; p=0·0006) after that age. Antibiotic 
prescription and atopy were independently associated 
with exacerbations and hospital admissions, and there 
was no interaction between them.
There was no eﬀ ect of antibiotic prescription on the 
development of atopy (table 4).
Stimulation data were available for 231 children 
(appendix), of whom 170 (74%) were prescribed at least 
one antibiotic and 61 (26%) had no antibiotics in the ﬁ rst 
year of life. There was no signiﬁ cant diﬀ erence in 
demographic characteristics, antibiotic prescription, and 
asthma or wheeze outcomes between children with and 
without stimulation data (appendix). Children who 
received antibiotics had signiﬁ cantly lower induction of 
IP10, interleukin 1β, and interferon α by RSV and 
rhinovirus 1B, and of interferon γ and TNFα by 
rhinovirus 1B (ﬁ gure 2, appendix). When we used 
number of antibiotic prescriptions as a continuous 
variable, with increasing number of prescriptions there 
was a signiﬁ cant decrease in interferon α, interleukin 1β, 
interleukin 6, and TNF in response to rhinovirus 1B, and 
a signiﬁ cant decrease in IP10 in response to all three 
viruses. There was no diﬀ erence in antibacterial 
responses between the groups (appendix).
When we used the same categories of antibiotic 
prescription as the ones we used for studies of antiviral 
and antibacterial immunity (at least one antibiotic or no 
antibiotics in the ﬁ rst year of life), we also showed that 
children who received antibiotics in the ﬁ rst year of life 
were signiﬁ cantly more likely to wheeze (HR 2·14, 
1·65–2·78; p<0·0001), have severe exacerbations 
(2·11, 1·26–3·50; p=0·004), and hospital admissions 
(2·66, 1·19–5·93; p=0·017; appendix) than those who 
received no antibiotics. Similar results were obtained for 
exacerbations or hospital admissions when limited to 
children with physician-conﬁ rmed or parentally-reported 
wheezing episode (appendix). When we assigned 
children into wheeze phenotypes,18 antibiotic prescription 
in infancy was associated with persistent and transient, 
but not late-onset wheeze (appendix).
We successfully completed genotyping in 700 children 
for SNP rs11557467, 782 for rs4795405, 777 for rs7216389, 
and 734 for rs3859192. For SNPs rs11557467 and 
rs4795405, there was a signiﬁ cant association with 
antibiotic prescription in the ﬁ rst year of life (table 5), in 
that children carrying G allele in ZPBP2 SNP rs11557467 
and those carrying C allele in ORMDL3 SNP rs4795405 
were at higher risk of being prescribed antibiotics 
(appendix). Further details are available in the appendix.
Discussion
In a longitudinal analysis from birth to age 11 years, we 
showed an association between early life antibiotic 
prescription and development of wheezing, but not 
atopy. To our knowledge, this is the ﬁ rst study to show 
that, in children with wheezing, antibiotic prescription in 
infancy increases the risk of subsequent severe wheeze 
or asthma exacerbations and hospital admissions 
(panel 2). To our knowledge, this is also the ﬁ rst study to 
report that children who receive antibiotics in infancy 
Atopic sensitisation
Antibiotic prescription in the ﬁ rst year of life 1·02 (0·60–1·78), p=0·92
Antibiotic prescription ever 1·66 (0·42–2·67), p=0·89
The age of antibiotic prescription
0–<3 months 1·08 (0·89–1·31), p=0·43
3–<6 months 1·08 (0·90–1·30), p=0·40
6–12 months 1·00 (0·86–1·18), p=0·96
>12 months 1·00 (0·84–1·19), p=0·99
Data are hazard ratio (95% CI).
Table 4: Eﬀ ect of antibiotic prescription on the development of atopic 
sensitisation during the ﬁ rst 11 years of life
Antibiotic 
prescription
Piecewise analysis of the age at antibiotic 
prescription
Time to event after the ﬁ rst antibiotic 
prescription
≤2 years >2 years
Severe wheeze or asthma exacerbation 1·75 (0·83–3·69), 
p=0·14
2·37 (0·98–5·73), p=0·054 (<3 months);
2·22 (0·93–5·29), p=0·07 (3–<6 months);
1·91 (0·79–4·63), p=0·15 (6–12 months);
1·97 (0·74–5·26), p=0·18 (>12 months)
2·09 (1·51–2·90), 
p<0·0001
1·01 (0·48–2·12), 
p=0·98
Hospital admission for asthma or wheeze 1·80 (0·55–5·86), 
p=0·33
2·96 (0·73–12·0), p=0·13 (<3 months);
2·28 (0·56–9·33), p=0·25 (3–<6 months);
2·14 (0·51–9·07), p=0·30 (6–12 months);
2·30 (0·45–11·6), p=0·32 (>12 months)
2·64 (1·49–4·70), 
p=0·0009
1·01 (0·31–3·25), 
p=0·99
Data are hazard ratio (95% CI), p value. Reference was no antibiotics received before given age. Analysis adjusted for sex, presence of older siblings, day care attendance, and 
breastfeeding.
Table 3: Antibiotic prescription and risk of severe asthma exacerbations and hospital admissions for asthma or wheeze among children with a history 
of wheezing
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have impaired antiviral immunity later in life, and that 
early life antibiotic prescription is associated with 
variants on chromosome 17q21 locus.
We collected data on antibiotic prescriptions issued by 
GPs and collected by parents; however, these data do not 
conﬁ rm that the antibiotics were taken. We also cannot 
exclude the possibility that antibiotics were prescribed 
when the child was away and could not be seen by his or 
her regular GP and were therefore not captured in our 
searches. However, the UK health-care system ensures 
that information on urgent or out-of-hours encounters 
and prescriptions by other health-care providers is sent 
to the patient’s GP and ﬁ led in their medical record.
We acknowledge that we have done multiple statistical 
tests. However, the associations we investigated are 
biologically plausible (and based on published work), and 
the outcomes are not independent. This might alleviate 
concerns about multiple testing.
We assessed antiviral and antibacterial immune 
responses in PBMCs collected at age 11 years, and do not 
have samples from early life, which predate antibiotic 
prescription. We therefore cannot exclude the possibility 
of reverse causation, for example by asthma or antibiotic 
use (perhaps via the eﬀ ect on the microbiome) altering 
adaptive immune responses to viruses.
One of the strengths of our study is that data on 
antibiotic prescriptions and outcomes were extracted 
from medical records, therefore eliminating recall bias. 
Medical records contained precise information (age in 
days) on the timing of prescription, onset of wheeze, 
asthma exacerbations, and hospital admissions. By 
knowing the exact age when the ﬁ rst antibiotic was 
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Figure 2: Analysis of immune response to viral stimuli
Interleukin 1β, interleukin 6, interferon γ, interferon α, TNFα, and IP10 protein concentrations in PBMC supernatants after stimulation with RV1B, RSV, and RV16 (all 
multiplicity of infection of 1). RV=rhinovirus. RSV=respiratory syncytial virus. TNF=tumour necrosis factor. IP10=interferon-γ-induced protein-10. PBMC=peripheral 
blood mononuclear cell.
Gene Location Allele* Number Number in each 
genotype group
One or more antibiotic prescriptions 
in the first year of life, OR (95% CI), 
p value
rs11557467 ZPBP2 Intron T/G† 700 TT 194, GT 344, GG 162 1·39 (1·10–1·75), p=0·006
rs4795405 ORMDL3 5' intergenic C†/T 782 CC 236, CT 371, TT 175 1·28 (1·03–1·59), p=0·02
rs7216389 GSDMB Intron C/T† 777 CC 215, CT 366, TT 196 1·22 (0·99–1·52), p=0·06
rs3859192 GSDMA Intron C/T 734 CC 240, CT 346, TT 148 1·09 (0·87–1·36), p=0·46
OR=odds ratio. SNP=single nucleotide polymorphism. *Common allele is listed ﬁ rst/rare allele second. †Risk allele (none for rs3859192 because of no association between 
this genetic variant and the risk of antibiotic prescription).
Table 5: Association between variants in 17q21 and antibiotic prescription in the ﬁ rst year of life by SNP
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received and when asthma-related outcomes occurred, 
we were able to account for reverse causation. We used 
data on both physician-conﬁ rmed and parentally reported 
wheeze, allowing more accurate deﬁ nition of wheezing.20
We excluded children who wheezed within 2 weeks of 
the ﬁ rst antibiotic prescription, because we deemed such 
wheeze to be a part of the same episode (likely respiratory 
tract infections), rather than a consequence of antibiotic 
prescription. We selected a 2-week cutoﬀ  on the basis of 
the ﬁ nding that about 90% of children attending day care 
recover from upper respiratory tract infections within 
2 weeks.21
Our results accord with the ﬁ ndings from the largest 
study so far,22 which showed a small increased risk of 
asthma after antibiotic prescription, and are consistent 
with another large study23 that identiﬁ ed that the 
association with antibiotic use was greater in early 
childhood asthma. Unlike previous work, our study 
includes an in-depth analysis of the temporal association 
between antibiotic use and asthma-related outcomes, 
showing that the risk was highest within 2 years after 
antibiotic prescription, and in children who received 
antibiotics in infancy. We postulate that this observation 
might be dominated by the chronological timing of the 
ﬁ rst receipt, and the noted eﬀ ects being conﬁ ned to early 
childhood. We speculate that children with increased 
susceptibility to infection (with its phenotypic marker of 
early life antibiotic receipt) might develop asthma 
symptoms in early life, thus resulting in the events 
occurring shortly after the antibiotic prescription. This 
notion is indirectly supported by our analyses, which 
showed that antibiotic prescription in infancy was 
associated with transient and persistent wheezing 
(phenotypes in which wheeze starts early in life), but not 
with late-onset wheezing (which is the phenotype 
predominantly associated with atopy). Our ﬁ ndings 
suggest that ignoring the temporal structure of the 
association of events might lead to misinterpretation of 
an apparent causal link between antibiotics and asthma.
In view of the known relation between asthma 
exacerbations and impaired antiviral immunity,11,24 our 
ﬁ nding that early life antibiotic prescription is associated 
with impaired antiviral immunity later in life links early 
antibiotic use with important, objectively measured 
biological outcomes. We noted that children who were 
prescribed antibiotics in infancy had signiﬁ cantly lower 
induction of cytokines later in life—which are important 
in host defence against virus infections. Of note, 
prescription of antibiotics in infancy was associated with 
impaired host response to both RSV and rhinovirus, but 
not to bacteria. We speculate that these in-vitro diﬀ erences 
might translate into the increased host susceptibility to 
virus infection, which could have predated antibiotic 
prescription. Such susceptibility might result in either 
increased frequency of infections, or altered response to 
infections (eg, making viral infections more prolonged or 
severe); hence, increasing the likelihood of medical 
consultations and the opportunity of receiving antibiotic 
prescription.25 Our ﬁ ndings suggest that the association 
between early life antibiotic prescription and asthma 
might arise as a result of confounding by indication, in 
which a hidden factor that results in both early life 
antibiotic prescription and the increased risk of childhood 
asthma, is an increased susceptibility to viral infections 
due to impaired antiviral immunity.
Our ﬁ nding that children who attend day care and have 
older siblings (both sources of viral transmission) were 
more often prescribed antibiotics is consistent with the 
notion that early life antibiotics are most commonly 
prescribed for viral respiratory tract infections.6,7 In view 
of the inappropriate prescribing of antibiotics (and the 
development of resistance that this might be causing), it 
may be helpful for primary care physicians considering 
the need to prescribe antibiotics for respiratory infections 
amongst wheezy children, to know that our data show 
that although antiviral immunity might be impaired, 
antibacterial immunity is not.
One biologically plausible mechanism by which 
antibiotic use might increase the risk of asthma is 
through an eﬀ ect on the microbiome, with consequent 
delays in immune maturation and increase in T-helper-2-
mediated diseases.26 In this context, the eﬀ ect of 
Panel 2: Research in context
Systematic review
We searched Medline via PubMed using variations of the keywords “antibiotics”, “atopy”, 
“childhood asthma”, “development” and “asthma exacerbations” with no date restrictions 
for articles published in English. We identiﬁ ed three systematic reviews and meta-analyses, 
summarising numerous studies which investigated the relation between early life 
antibiotic use and childhood asthma.1-3 All systematic reviews reported conﬂ icting results 
between diﬀ erent studies, and called for further longitudinal studies to provide deﬁ nitive 
answers. Retrospective and cross-sectional studies showed much stronger association 
than prospective studies,1, 2 suggesting that bias rather than causal relation could explain 
the association between antibiotics and asthma. No previous studies included an in-depth 
analysis of the temporal association between antibiotic prescription and asthma-related 
outcomes, or the relation between antibiotic prescription and antiviral or antibacterial 
immune responses, or potential genetic associations of early life antibiotic prescription.
Interpretation
To our knowledge, this is the ﬁ rst detailed study to disentangle the temporal association 
between antibiotic use and asthma-related outcomes. In a longitudinal analysis from birth 
to age 11 years done in a population-based birth cohort study, we have conﬁ rmed a small 
increased risk of asthma (but not atopic sensitisation) after antibiotic prescription. To our 
knowledge, our study is the ﬁ rst to show that in children with wheezing, antibiotic 
prescription in the ﬁ rst year of life increases the risk of subsequent severe exacerbations of 
wheeze or asthma, and hospital admissions. This is also to our knowledge the ﬁ rst study to 
show that children who receive antibiotics in the ﬁ rst year of life have impaired antiviral 
immunity later in life, and that early life antibiotic prescription is associated with genetic 
variants on chromosome 17q21 locus. Our ﬁ ndings suggest that the association between 
antibiotics and childhood asthma arises through a complex confounding by indication, in 
which hidden factors which increase the likelihood of both antibiotic prescription in early 
life and subsequent asthma development, are an increased susceptibility to virus infections 
consequent to impaired antiviral immunity, and genetic variants on 17q21.
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antibiotics would be expected to be stronger on atopy 
than on asthma. However, our analysis showed no eﬀ ect 
of antibiotic prescription on atopy; by contrast, the eﬀ ect 
on wheezing was strong. Reports that maternal use of 
antibiotics during pregnancy27 or giving of antibiotics 
during delivery28 is associated with an increased risk of 
asthma in oﬀ spring have been interpreted in support of 
the hypothesis that the association of antibiotics with 
asthma is mediated through modiﬁ cation of bacterial 
ecology prenatally or in early life.27 Alternatively, maternal 
antibiotic usage might be a marker of impaired antiviral 
immunity in the mother, and this susceptibility might be 
genetically (or epigenetically) transmitted to the child.
We have shown that early life antibiotic prescription is 
associated with variants on the chromosomal locus 17q21. 
We have previously reported in the same population a 
strong association between wheeze and severe asthma or 
wheeze exacerbations and polymorphisms in this 
region.29 We have no data to suggest the mechanism by 
which 17q21 variants might aﬀ ect the onset of wheezing 
(or antibiotic prescription); whether these variants might 
increase the risk of infection per se, and what their 
relation with antimicrobial immunity is, warrant further 
research. 17q21 variants oﬀ er another hidden confounder 
of the association between early life antibiotics and 
asthma, with bias arising through gene–environment 
correlations.30 This raises an important issue that eﬀ ects 
that are often attributed to environmental exposures 
might be related to genetic predisposition.
Future studies should account for the possibility that 
environmental exposures might not occur at random, 
but might be dependent on the individual’s genotype 
(such as early life antibiotic prescription occurring 
more commonly amongst individuals with speciﬁ c 
17q21variants).
In conclusion, the association between antibiotic use 
and childhood asthma might arise as a result of complex 
confounding by indication, in which hidden factors that 
increase the likelihood of both early life antibiotic 
prescription and later asthma, may include increased 
susceptibility to viral infections as a consequence of 
impaired antiviral immunity, and genetic variants on 
17q21. Whether impaired antiviral immunity predated 
antibiotic use making antibiotic prescription more likely, 
or whether it is also a consequence of antibiotic use, will 
need further studies monitoring antiviral immunity 
throughout early and later childhood.
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